Techniques to Determine Clonality in Hematolymphoid Malignancies

  • Daniel E. Sabath
Part of the Molecular Pathology Library book series (MPLB, volume 4)


Clonality testing is a well-established molecular diagnostic technique in the realm of hematopathology. Molecular techniques to diagnose hematological malignancies based on the detection of clonality have been with us since the mid-1980s, based on the seminal observation that lymphoid cells rearrange their antigen receptor genes and that recurrent genetic rearrangements are present in myeloid neoplasms. In this chapter, I review the history of clonality testing in cancer, describe the scientific principles on which clonality-based testing rest, and then describe the numerous techniques that are now available for diagnosing hematolymphoid malignancies by demonstrating their clonal nature.


Cell Clonality Antigen Receptor Androgen Receptor Gene FLT3 Mutation Clonal Nature 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Knudson AGJ. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820–823.CrossRefPubMedGoogle Scholar
  2. 2.
    Lyon MF. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet. 1962;14:135–148.PubMedGoogle Scholar
  3. 3.
    Beutler E, Yeh M, Fairbanks VF. The normal human female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD-deficiency as a marker. Proc Natl Acad Sci U S A. 1962;48:9–16.CrossRefPubMedGoogle Scholar
  4. 4.
    Fialkow PJ. Clonal origin of human tumors. Biochim Biophys Acta. 1976;458:283–321.PubMedGoogle Scholar
  5. 5.
    Brown CJ, Lafreniere RG, Powers VE, et al. Localization of the X inactivation centre on the human X chromosome in Xq13. Nature. 1991;349:82–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Brown CJ, Hendrich BD, Rupert JL, et al. The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell. 1992;71:527–542.CrossRefPubMedGoogle Scholar
  7. 7.
    Sleddens HFBM, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res. 1992;20:1427.CrossRefPubMedGoogle Scholar
  8. 8.
    Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229–1239.PubMedGoogle Scholar
  9. 9.
    Chen GL, Prchal JT. X-linked clonality testing: interpretation and limitations. Blood. 2007;110:1411–1419.CrossRefPubMedGoogle Scholar
  10. 10.
    Burnet FM. Immunological recognition of self. Science. 1961;133:307–311.CrossRefPubMedGoogle Scholar
  11. 11.
    Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med. 2006;130:680–690.PubMedGoogle Scholar
  12. 12.
    Weiss LM, Movahed LA, Chen YY, et al. Detection of immunoglobulin light-chain mRNA in lymphoid tissues using a practical in situ hybridization method. Am J Pathol. 1990;137:979–988.PubMedGoogle Scholar
  13. 13.
    Bagg A, Braziel RM, Arber DA, Bijwaard KE, Chu AY. Immunoglobulin heavy chain gene analysis in lymphomas: a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays. J Mol Diagn. 2002;4:81–89.PubMedGoogle Scholar
  14. 14.
    van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–2317.CrossRefPubMedGoogle Scholar
  15. 15.
    Catherwood MA, Gonzalez D, Patton C, Dobbin E, Venkatraman L, Alexander HD. Improved clonality assessment in germinal centre/post-germinal centre non-Hodgkin’s lymphomas with high rates of somatic hypermutation. J Clin Pathol. 2007;60:524–528.CrossRefPubMedGoogle Scholar
  16. 16.
    Liu H, Bench AJ, Bacon CM, et al. A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality in diagnostic haematopathology. Br J Haematol. 2007;138:31–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Morice WG, Kimlinger T, Katzmann JA, et al. Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. Am J Clin Pathol. 2004;121:373–383.CrossRefPubMedGoogle Scholar
  18. 18.
    Quertermous T, Murre C, Dialynas D, et al. Human T-cell gamma chain genes: organization, diversity, and rearrangement. Science. 1986;231:252–255.CrossRefPubMedGoogle Scholar
  19. 19.
    Sprouse JT, Werling R, Hanke D, et al. T-cell clonality determination using polymerase chain reaction (PCR) amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled PCR products. Am J Clin Pathol. 2000;113:838–850.CrossRefPubMedGoogle Scholar
  20. 20.
    Lee S-C, Berg KD, Racke FK, Griffin CA, Eshleman JR. Pseudo-spikes are common in histologically benign lymphoid tissues. J Mol Diagn. 2000;2:145–152.PubMedGoogle Scholar
  21. 21.
    Greiner TC, Rubocki RJ. Effectiveness of capillary electrophoresis using fluorescent-labeled primers in detecting T-cell receptor g gene rearrangements. J Mol Diagn. 2002;4:137–143.PubMedGoogle Scholar
  22. 22.
    Kuo FC, Hall D, Longtine JA. A novel method for interpretation of T-cell receptor gamma gene rearrangement assay by capillary gel electrophoresis based on normal distribution. J Mol Diagn. 2007;9:12–19.CrossRefPubMedGoogle Scholar
  23. 23.
    Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today. 1996;17:86–91.CrossRefPubMedGoogle Scholar
  24. 24.
    Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739–751.CrossRefPubMedGoogle Scholar
  25. 25.
    Pascal V, Schleinitz N, Brunet C, et al. Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions. Eur J Immunol. 2004;34:2930–2940.CrossRefPubMedGoogle Scholar
  26. 26.
    Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47:19–28.CrossRefPubMedGoogle Scholar
  27. 27.
    Bosch F, Jares P, Campo E, et al. i PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84:2726–2732.PubMedGoogle Scholar
  28. 28.
    Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science. 1983;219:963–967.CrossRefPubMedGoogle Scholar
  29. 29.
    Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–1284.CrossRefPubMedGoogle Scholar
  30. 30.
    Lamant L, Gascoyne RD, Duplantier MM, et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2003;37:427–432.CrossRefPubMedGoogle Scholar
  31. 31.
    Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93:3601–3609.PubMedGoogle Scholar
  32. 32.
    Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene. 2007;26:1297–1305.CrossRefPubMedGoogle Scholar
  33. 33.
    Gulley ML, Raab-Traub N. Detection of Epstein-Barr virus in human tissues by molecular genetic techniques. Arch Pathol Lab Med. 1993;117:1115–1120.PubMedGoogle Scholar
  34. 34.
    Harrington WJJ, Miller GA, Kemper RR, Byrne GEJ, Whitcomb CC, Rabin M. HTLV-I-associated leukemia/lymphoma in south Florida. J Acquir Immune Defic Syndr. 1991;4:284–289.PubMedGoogle Scholar
  35. 35.
    Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.Google Scholar
  36. 36.
    Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293.CrossRefPubMedGoogle Scholar
  37. 37.
    Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93–99.CrossRefPubMedGoogle Scholar
  38. 38.
    Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.CrossRefPubMedGoogle Scholar
  39. 39.
    Grimwade D, Walker H, Oliver F, et al. Parties MRCAaCLW. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–2333.PubMedGoogle Scholar
  40. 40.
    Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336.CrossRefPubMedGoogle Scholar
  41. 41.
    Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66.CrossRefPubMedGoogle Scholar
  42. 42.
    Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107:3724–3726.CrossRefPubMedGoogle Scholar
  43. 43.
    Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335.CrossRefPubMedGoogle Scholar
  44. 44.
    Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111:1552–1559.CrossRefPubMedGoogle Scholar
  45. 45.
    Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5:96–102.PubMedGoogle Scholar
  46. 46.
    Scholl S, Krause C, Loncarevic IF, et al. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. J Lab Clin Med. 2005;145:295–304.CrossRefPubMedGoogle Scholar
  47. 47.
    Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011–4020.CrossRefPubMedGoogle Scholar
  48. 48.
    Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733–3739.CrossRefPubMedGoogle Scholar
  49. 49.
    Szankasi P, Jama M, Bahler DW. A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn. 2008;10:236–241.CrossRefPubMedGoogle Scholar
  50. 50.
    Roti G, Rosati R, Bonasso R, et al. Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn. 2006;8:254–259.CrossRefPubMedGoogle Scholar
  51. 51.
    Ottone T, Ammatuna E, Lavorgna S, et al. An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn. 2008;10:212–216.CrossRefPubMedGoogle Scholar
  52. 52.
    Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999–2005.CrossRefPubMedGoogle Scholar
  53. 53.
    Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19:329–334.CrossRefPubMedGoogle Scholar
  54. 54.
    Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27:263–270.CrossRefPubMedGoogle Scholar
  55. 55.
    Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717–2723.CrossRefPubMedGoogle Scholar
  56. 56.
    Valk PJM, Verhaak RGW, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617–1628.CrossRefPubMedGoogle Scholar
  57. 57.
    Juhl-Christensen C, Bomberg M, Melsvik D, Hokland P, Nyvold CG. Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia (AML). Eur J Haematol. 2008;81:273–280.CrossRefPubMedGoogle Scholar
  58. 58.
    Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107:4214–4222.CrossRefPubMedGoogle Scholar
  59. 59.
    Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006;8:397–411.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Daniel E. Sabath
    • 1
  1. 1.Departments of Laboratory Medicine and MedicineUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations